INDEX

Acetoxycycloheximide, effect on memory, 13–14
N-Acetyl aspartate, proton magnetic resonance spectroscopic assessment of, 15
Acquired immunodeficiency syndrome (AIDS) defining conditions of, 29
as developmental abnormalities cause, 29
intravenous drug abusers’ susceptibility to, 83
neurological complications of, 29
T-cell circulation homeostasis in, 97–98
Acquired immunodeficiency syndrome (AIDS) dementia complex, 29–34
direct neurotoxicity in, 30
indirect neurotoxicity in, 30–32
monocyte chemotactic protein-1 levels in, 259
Addiction
hypothalamic-pituitary-adrenal axis abnormalities in, 59–64
susceptibility to, of inbred rat strains, 62–65
Adhesion molecules, morphine-induced expression of, 188–190, 194
Adrenal gland, cannabinoid receptor 1 distribution in, 216
Adrenocorticotropin hormone, in proopiomelanocortin pathway, 62, 63
After hyperpolarization suppression, 19–20
Alcohol use
neurotoxicity of, 7
regulatory genomic loci in, 64
Aminohydrolol, intestinal content of, 198
Amphetamines, neurotoxicity of, 7
Anandamide degradation of, 198
effect on peritoneal macrophage phagocytosis, 207–208
Angiitis, necrotizing, opiate abuse-related, 203
Animal model
of cognitive function assessment, 9–14
hippocampal models, 15–21
in HIV-related cognitive dysfunction, 21
passive avoidance tests (PAT), 13–14
prototypical paradigms for, 9, 10
radial arm-maze (RAM), 9, 10
inbred rat strains, susceptible to experimental autoimmune disease, 60–61
hypothalamic-pituitary-axis abnormalities in, 62
Animal model (cont.)
inbred rat strains, susceptible to experimental autoimmune disease (cont.)
relationship with addiction susceptibility, 62–65
relationship with autoimmune disease, 63–65
of intravenous cocaine abuse, 241–245
MORKO (μ-opioid receptor-deficient) mice
effect of chronic morphine injection on, 117–124
corticosterone levels in, 120–121, 122–123, 124
production of, 117–118
Anxiety, drug withdrawal-related, 63
Apoptosis
Fas-dependent, CD8+ T cell resistance to, 150
in Friend leukemia virus infection, effect of antiretroviral therapy on, 143–152
in HIV-related neurodegeneration, 30–31
morphine-induced, 163
of T cells, opiates-induced, 127–135
e-Jun NH2-terminal kinase and extracellular signal related kinase pathways in, 127, 128
130–133
Apoptotic cells, heroin-related increase in, 156–159, 160–161
Apparent diffusion coefficient of water (ADC), 15
2-Arachidonylglycerol, intestinal content of, 198
Astrocytes
HIV infection of, 31–32
as latent infection, 32
as HIV reservoir, 29–30
Astrogliosis, in HIV-related encephalopathy, 259
ATF-2, in opiate-induced T-cell apoptosis, 127,130, 131, 132
Autoimmune disease
β-endorphins in, 140–141
experimentally-induced, genomic loci of, 64–65
genetic factors in, 59–67
hypothalamic-pituitary-adrenal axis abnormalities in, 59–64
Azidothymidine (AZT)
antiapoptotic effect of, 150
effect on Fas/Fasl expression, 144, 147, 148, 149, 150
Bacterial infections, see also specific bacteria neurotropic, 2

B cells
heroin-related decrease in, 152–153, 159–160
lipopolysaccharide-stimulated, cannabinoid receptor2 mRNA expression in, 223–228

Bcl-2, apoptosis-blocking mechanism of, 133

Bcl-XL, apoptosis-blocking mechanism of, 133

Benzodiazepines, HIV-suppressing action of, 3

Bidlack, Jean, 256–257

Bone marrow, cannabinoid receptor1 mRNA localization of, 215–221

Blood-brain barrier
in HIV infection, 35, 36
effect of cocaine on, 38–39
viral penetration in, 35–36, 38–39

μ-opioid receptor-induced permeability of, 188, 194–195

Blood flow, cerebral in cognitive deficits, 15 in HIV infection, 260, 261

Blood lymphocyte proliferation, in morphine tolerance, 177–185
c-fos expression in, 178, 179, 181, 182, 183
delayed-hypersensitivity response in, 178, 179, 180, 182, 183
paraventricular nucleus in, 178, 181, 182, 183

Bone marrow, cannabinoid receptor1 distribution in, 216

Bost, Kenneth L., 264

Bowel stasis, in salmonellosis, effect of morphine on, 174

Brain
cannabinoid receptor1 distribution in, 216
as immunologically-privileged site, 1
Brain-derived neurotrophic factor expression in HIV-related encephalitis, 42 functions of, 41
effect on HIV replication in macrophages, 43–46

Brain microvascular endothelial cells (BMVEC) chemokine receptors on, HIV binding with, 35–40 in Escherichia coli infections, 35 in HIV infection, 36–39

HIV invasion of, 36–39
morphine-induced permeability of, 190
morphine-induced viability decrease in, 190–192, 194–195

morphine/lipopolysaccharide-induced viability decrease in, 192–193

morphine-mediated adhesion cell expression on, 189–190, 194
therapeutic applications of, 195

Cabras, Guy, 255–256

Calcium, intracellular
in HIV-related neurotoxicity, 32

substance P receptor-induced mobilization of, 248

Cancer, intravenous drug abusers’ susceptibility to, 83

Cannabinoid(s)
intestinal motility inhibition by, 197

Cannabinoid(s) (cont.)
macrophage modulation by, 207–208

effect on microglia, 3

neurotoxicity of, 7

nitric oxide inhibition by, 207–214

nitric oxide synthase levels in, 211–212, 213
reversal of, 207, 210–211

Cannabinoid receptor(s)
of enteric nervous system, 198, 199

mRNA of, expression in human peripheral blood mononuclear cells, 229–233

Cannabinoid receptor1 expression in microglial cells, 211, 213
localization of, 208, 213, 255–256
mRNA of, expression on activated murine splenocytes, 215–221

nitric-oxide inhibitory action of, 208, 212–213

source of, 216

Cannabinoid receptor2 localization of, 208, 213, 255–256
mRNA expression by, in lipopolysaccharide-stimulated cells, 223–228

Caspases, in opiate-induced T-cell apoptosis, 127, 128, 131–133

CD4+/CD62L− T cells, morphine-induced homeostasis of, 82–101
use in T-cell activation measurement, 103–104, 105

CD4+ T cells
Fas-mediated apoptosis-induced cell death in, 143 in human T-cell leukemia virus type-1 infection, 49
latent HIV infection of, 32
mitogen activation of, effect on κ-opioid receptor expression, 103–110

CD8+ T cells
Fas-dependent apoptosis resistance of, 143, 150

mitogen activation of, effect on κ-opioid receptor expression, 103–110

CD28, in opioid-induced T cell apoptosis, 133

CD69 cell surface antigen in lipopolysaccharide-stimulated B cells, 226
use in T-cell activation measurement, 103–104, 105

Center for Neurology and Neurodegenerative Disorders (CNND), 8

Centers for Disease Control and Prevention, AIDS-defining conditions identification by, 29

Central nervous system infections
HIV-related, 29–34

inflammatory cascade in, 7, 8

mortality rates in, 1

Cerebrospinal fluid, HIV accessory proteins in, 30
c-fos, expression in morphine tolerance, 178, 179, 181, 182, 183

Chang, Linda, 260–261

Chang, Sulie, 264

Chemokine receptors
on brain endothelia in HIV infection, 35–40
cocaine-modulated gene expression of, 238–239
Edema, cytotoxic or vasogenic, 14–15
Eisenstein, Toby K., 263
Encephalitis
AIDS/HIV-related, 21, 42
microglial cells in, 208
experimental autoimmune, β-endorphins in, 140–141
Encephalomyelitis, experimentally-induced
inbred rat strains’ resistance to, 61
inbred rat strains’ susceptibility to, 60–61
Encephalopathy, HIV-related
effect of intravenous drug abuse on, 259
in pediatric patients, 29
Endomorphin-1, 3
β-Endorphins
in autoimmune, 140–141
production of, 62, 137
effect on skin graft survival time, 140, 141
effect of Th1/Th2 balance, 137–141
Endothelial leukocyte adhesion molecule (ELAM)
cocaine-induced secretion of, 39
morphine-induced secretion of, 189–190
Enkephalins, see also DAGL, DAMO, DPDPE
Methionine enkephalin
expression in enteric neurons, 198
production of, 62
effect on thymic T cell development, 165–166
Enteric nervous system, functions of, 197
Enteric neurons
opioid and cannabinoid receptor expression in, 198–199
Peyer’s patches, innervation by, 202
Enterides, necrotizing, opiate abuse-related, 203
Enteropathogen invasion, neuroregulation of, 201–202
Env protein, as HIV infection marker, 31
Escherichia coli, central nervous system invasion by, 35
Excitatory post-synaptic potential, 16, 17
FADD (Fas-associated death domain-containing protein), 128/132
Fas, morphine-enhanced expression of, 128
Fas-associated death domain-containing protein (FADD), 128, 132
Fas/FasL, in Friend leukemia virus disease
pathogenesis, 143–152
FasL, effect on apoptosis-induced cell death, 143
Fetal thymic organ culture, effect of staphylococcal enterotoxin B on, 163–167
β-Funaltrexamine, 3
Friend leukemia virus disease
Fas/FasL expression in, 143–152
as HIV infection model, 143–144
Fungal infections, neurotropic, 2
Gag protein, as HIV infection marker, 31
GALT (gut-associated lymphoid tissue), 197, 201
Gastrointestinal tract, endogenous flora, morphine-associated translocation of, 174
Gendelman, Howard, 259–260
Glia, in HIV-related neurodegeneration, 30–31, 32–33
Glucose uptake studies, of cognitive function, 15
Glutamate, HIV-related increase in, 32
Glutaminergic neurons, cooperativity of, 20–21
Glycoprotein, in HIV-related neurodegeneration, 30, 31
Glycoprotein 41
in HIV-associated dementia, 260
in HIV-associated neurodegeneration, 31
Glycoprotein 120, neurotoxicity of, in cocaine abuse, 243, 244
Gut-associated lymphoid tissue (GALT), 197, 201
Heart, cannabinoid receptor distribution in, 216
Heroin
as HIV infection risk factor, 153
effect on leukocyte chemotaxis, 70
effect on splenic cellularity, 153–162
apoptotic cell increase, 156–159, 160–161
B cell proliferation decrease, 152–153, 159–160
interferon-γ decrease, 152–154, 159–160
leukocyte apoptosis rate in, 156–159, 160–161
leukocyte decrease, 141–150, 154–156, 160, 161
natural killer cell cytotoxicity decrease, 152–154, 155, 159, 161
T cell proliferation decrease, 152–153, 155, 159–160
total leukocyte number in, 155, 161
Heroin abusers, number of, 241
Herpes simplex virus infections, 1
Herpes virus infections, effect of morphine on, 3
Highly-active antiretroviral therapy (HAART), 32, 261
Hippocampus, role in memory formation, 15–21
cAMP/CREB/CBP pathways in, 18–20
cooperativity mechanism in, 20–21
excitatory post-synaptic potential in, 16, 17
long-term depression in, 20
long-term potentiation in, 16, 18–20
neurophysiology of, 16–17
Histamine, as intestinal inflammatory mediator, 200, 201
HIV, see Human immunodeficiency virus
HL-60 promyelocytic leukemia cells, morphine-potentiated cytokine production in, 193–194, 195
HU-210, 201
Human fetal microglial cells, κ-opioid receptor
eexpression on, 108–109
Human immunodeficiency virus (HIV)
chemokine co-receptors for, 235, 239
coinfection with human T-cell leukemia virus-1, 49–58
effect of morphine on, 48–57
protein 19 levels in, 50–55, 56, 57
intestinal invasion by, 202
Index

Human immunodeficiency virus (cont.)
microglial cell targeting by, 1
penetration of blood-brain barrier by, 35–36
effect of cocaine on, 38–39
Human immunodeficiency virus (HIV) infection of central nervous system, 29–34
cocaine-suppressed MIP-β synthesis in, 235–240
highly active antiretroviral therapy (HAART) for, 32
latency of, 32
of microglia, effect of μ-opioid receptor agonists on, 3
Salmonella infections associated with, 170, 173
Human immunodeficiency virus (HIV) proteins, see also Glycoprotein 120. Tat protein in HIV-related neurogeneration, 30
Human T-cell leukemia virus type-1 (HTLV-1) coinfection with HIV, 49–58
effect of morphine on, 48–57
protein 19 levels in, 5–55, 56, 57
infection rates, 49
Humoral immune response, substance P receptors in, 250–251, 252
Hypothalamic-pituitary-adrenal axis abnormalities, in autoimmune disease and addiction, 59–64
Immunoglobulin A, secretory generation by mucosa-associated lymphoid tissue, 197
transfer of, 199
Inbred rat strains, susceptibility to experimental autoimmune disease, 60–61
hypothalamic-pituitary-axis abnormalities in, 62
relationship with addiction susceptibility, 62–65
relationship with autoimmune disease, 63–65
Inflammatory cascade, in central nervous system infections, 7, 8
Inner submucosal plexus, 198
Intercellular adhesion molecules
cocaine-induced expression of, 39
morphine-induced expression of, 189–190
Interferon-γ
cocaine-induced secretion of, 39
heroin-related decrease in, 152–153, 159–160
in substance P receptor-mediated signaling, 250
effect on substance P receptor mRNA expression, 251, 253
Th1-generated, 138
effect of naloxone on, 139
in skin grafts, 140
Interferon-inducible protein-10, cocaine-induced secretin of, 39
Interleukin-1
β-endorphin-stimulating action of, 137
functions of, 188
lipopolysaccharide-induced secretion of, 187–188
μ-opioid agonist-induced inhibition of, 70
Interleukin-1 (cont.)
morphine-induced inhibition of, in μ-opioid receptor-knockout mice, 82
peritoneal macrophage production of, U50,488-related inhibition of, 103
Interleukin-1b, effect on HIV-infected astrocytes, 259
Interleukin-2
apoptosis-inhibiting action of, 133
Th-1-generated, 138
effect of naloxone on, 139
in skin grafts, 140
Interleukin-4
effect on substance P receptor mRNA expression, 251, 253
Th2-generated, 138
effect of naloxone on, 138
Interleukin-5, Th2-generated, 138
Interleukin-6
cocaine-induced secretion of, 39
HIV-induced, in brain microvascular endothelial cells, 38
μ-opioid agonist-induced inhibition of, 70
morphine-related inhibition of, in μ-opioid receptor-knockout mice, 82
mRNA, calcium-mobilizing agonists-mediated induction of, 248
nuclear factor-κB-related upregulation of, 249
peritoneal macrophage production of, U50,488-related inhibition of, 103
Th2-generated, 138
Interleukin-8
cocaine-induced secretion of, 39
lack of effect on opioid-induced chemotaxis, 78
lack of opioid agonist desensitizing effects, 72, 73
Interleukin-10
effect on chemokine receptor expression, 71
cocaine-induced suppression of, 39
Th2-generated, 138
Interleukin-12
antipoptotic effect of, in Friend leukemia virus infections, 150
μ-opioid receptor-inducing action of, in brain microvascular endothelial cells, 187–188
substance P antagonist-related decrease in, 250
substance P co-stimulation of, 248–249, 252
Interleukin-12p35, nuclear factor-κB-related upregulation of, 249
Interleukin-12p40, nuclear factor-κB-related upregulation of, 249
Interleukin-13, Th2-generated, 138
Intestinal tract
flora of, morphine-enhanced growth of, 201
pharmaconeuroimmunology of, 197–205
neuroregulation of enteropathogen invasion, 201–203
opioid and cannabinoid mediation of mucosal secretory defenses, 199–201
Intracellular signaling in HIV-related neurodegeneration, 30–32
Substance P receptors in, 247–248
Intravenous drug abuse
Animal model of, 241–245
Human T-cell leukemia virus type-1 infection transmission via, 49
As salmonellosis risk factor, 170
Intravenous drug abusers
AIDS progression in, 97–98
AIDS susceptibility of, 83
Cancer susceptibility of, 83
Opportunistic susceptibility of, 83
Jurkat cells, cannabinoid receptor, expression in, 200
Kallidin, as intestinal inflammatory mediator, 200, 201
Keratinocytes, human HaCaT, opioid responsiveness of, 75–79
Kidneys, cannabinoid receptor, distribution in, 216
KOR, see μ-opioid receptors
Lead, neurotoxicity of, 7
Leukocyte circulation, effect of opioids on, 83
Leukocyte-endothelial interactions, 187
Leukocytes, heroin-related decrease in, 154–156, 160, 161
Lymphoencephalopathy, progressive multifocal, 29
Lipopolysaccharide effect on B-cell cannabinoid receptor, mRNA expression, 223–228
Chemokine receptor downregulation by, 227
Interaction with morphine, 187–196
In cytokine production, 193–194
Effect on brain microvascular endothelial cell viability, 192–193
Long-term depression, 20
Long-term potentiation, 16, 18–20
LSD (lysergic acid diethylamide), neurotoxicity of, 7
Lungs, cannabinoid receptor, distribution in, 216
Lymphocytes
CEMxT4, κ-opioid receptor mRNA expression in, 81–87
κ-opioid receptors of, morphine-induced upregulation of, 81–87
Transmembrane G-protein coupled receptor-induced modulation of, 255–258
Lymphoma
Adult T cell, 49
Of central nervous system, 29
Lymphoproliferation, β-endorphin-induced decrease in, 137–138
Lymphotoxins, Th1-generated, 138
Macrophage cell line P388D, μ-opioid agonist-inhibition of, 70
Macrophage inflammatory protein-1α effect on brain microvascular endothelial cell migration, 36–37
Chemotaxis-inducing action of, 70, 71
Cocaine-induced secretion of, 39
HIV entry co-receptor binding by, 235
Opioids-induced inhibition of, 71
Macrophage inflammatory protein-1β effect on brain microvascular endothelial cell migration, 36–37
HIV entry co-receptor binding by, 235
Macrophage inflammatory protein-3β, effect on opioid-induced chemotaxis, 76, 77, 78
Macrophages
Definition of, 1
HIV replication in, neurotrophic factor regulation of, 41–47
Interaction with substance P receptors
Immune response amplification in, 252–253
Intracellular signaling in, 247–248
Monokine secretion in, 248–249
Preprotachykinin expression in, 249
In salmonellosis, 249–250
κ-opioid receptor expression by, 108
Peritoneal, μ-opioid receptors of, 256–257
Phagocytosis by effect of anandamide on, 207–208
Effect of opioid-selective agonists on, 69–70
Self-enhanced, effect of morphine on, 111–116
Magnetic resonance techniques for cognitive function assessment, 14–15
For HIV-related neuropathogenesis evaluation, 260–261
Major, Eugene, 259–260
Memory deficits, drug abuse-related, 7
Meningitis, pneumococcal, case fatality rate in, 1
Mesenteric lymph nodes, morphine-enhanced Salmonella growth in, 170, 171, 172, 174
Methamphetamine abusers
HIV infection in, 261
Number of, 241
Methionine-enkephalin expression by CD4 cells, 163
Effect on Fas/FasL expression, 144, 147, 148, 149, 150
As Friend leukemia virus infection therapy, 143–152
Effect on leukocyte chemotaxis, 70
N-Methyl-D-aspartate glutamate (NMDA) receptors in hippocampal long-term potentiation, 20–21, 22
In HIV-related neurodegeneration, 32
Microglia
In brain damage and repair, 2
Cannabinoid receptors of, 256
Cytokine production by, 256
Differentiation of, 2
HIV infection of, 2
Effect of μ-opioid receptor agonists on, 3
Morphine tolerance
altered T-cell responsiveness in, 177–185
c-fos expression in, 178, 179, 181, 182, 183
delayed-type hypersensitivity response in, 178, 179, 180, 182, 183
paraventricular nucleus in, 178, 181, 182, 183
antinociceptive effect in, 178–179, 180, 181
Mucosal secretory defenses, gastrointestinal, effect of opioids and cannabinoids on, 199–201
Mucous membranes, host defense mechanisms of, 197
Myelopathy, human T-cell leukemia virus type-1 infection-associated, 49
Myenteric plexus, 198
Myoinositol, in HIV infection neuropathogenesis, 260–261
Naloxone
effect on HIV/human T-cell leukemia virus-1 coinfections, 51, 52–53, 54, 55, 56
effect on KLH-stimulated cytokine production, 138, 139–140
effect on morphine-related upregulation of \(\kappa\)-opioid receptors, 81, 82–83, 86
effect on skin graft survival time, 140
effect on Th1 and Th2 cytokine production, 138, 139–140
Naltrindole, 82–83, 86
thymocyte proliferation-enhancing action of, 165–166
Natural killer cells
\(\beta\)-endorphin-induced stimulation of, 137–138
heroin-induced cytotoxicity decrease in, 152–153, 155, 159, 161
nef protein, as HIV infection marker, 31
Nerve growth factor
effect of HIV replication in macrophages, 43–46
mRNA of, HIV-induced expression of, 42
Neurodegeneration
AIDS dementia complex-related
direct neurotoxicity in, 30
indirect neurotoxicity in, 30–32
models of, 7
Neuroimaging studies
cognitive function assessment, 14–15
of HIV infection, 260–261
Neurokinin A, neurokinin receptor subtype binding affinity of, 251
Neurokinin B, neurokinin receptor subtype binding affinity of, 251
Neurotrophic factors, effect on HIV replication in macrophages, 41–47
Nicotine, neurotoxicity of, 7
Nitric oxide
cannabinoid-mediated inhibition of, 256
in HIV infection-related neurodegenerative disorders, 31, 208
Nitric oxide (cont.)
inducible, cannabinoid-mediated inhibition of, 207–214
nitric oxide synthase levels in, 211–212, 213
reversal of, 207, 210–211
Norepinephrine, stress-induced, effect on T-cell circulation, 96–97
Nuclear factor-κB
in monocyte chemotactic protein-1 upregulation, 259
substance P receptor-induced translocation of, 247, 248, 252
Opiate abuse, gastrointestinal disorders associated with, 203
Opiates
effect on HIV infection, 8
neurotoxicity of, 7
Opioid(s)
as antidiarheal agents, 197
contraindications to, 203
immunomodulatory properties of, 2–3
\(\delta\text{-Opioid}\) receptor(s)
dimerization with \(\kappa\text{-opioid}\) receptors, 82
of enteric nervous system, 198–199
expression on activated splenocytes, 109
of immune system, 69
mRNA expression by, 256
in opioid-induced chemotaxis suppression, 82
\(\delta\text{-Opioid}\) receptor agonists, 2
effect on thymic T cell development, 163–167
\(\kappa\text{-Opioid}\) receptors
dimerization with delta-opioid receptors, 82
of enteric nervous systems, 199
expression on human fetal microglial cells, 108–109
expression on mitogen-activated lymphocytes, 103–110
CD69 measurement in, 103–104, 105
flow cytometric analysis of, 103, 106
indirect immunofluorescence measurement of, 103–105, 106
effect on gastrointestinal transit time, 174
of immune system, 69
of lymphocytes, morphine-induced upregulation of, 81–87
of microglia, 256–257
\(\kappa\text{-Opioid}\) receptor ligands, HIV-suppressive action of, 3
\(\mu\text{-Opioid}\) receptor(s)
elimination of, in animal models, 117–126
of enteric nervous system, 199
gastrointestinal transit inhibitory action of, 174
of immune system, 69
interleukin-1α-induced expression of, 188
interleukin-1β-induced expression of, 188
lipopolysaccharide-induced expression of, 187–188
on HL-60 promyelocytic leukemia cells, 193–194
morphine binding with, 81
\(\mu\text{-Opioid}\) receptor(s) (cont.)
morphine-induced expression of, in brain
microvascular endothelial cells, 188
of morphine-treated cells, effect on plasma corticosterone levels, 120–121, 122, 124
in opioid-induced chemotaxis suppression, 82
in opioid-induced T-cell apoptosis, 133
\(\mu\text{-Opioid}\) receptor agonists, 2
effect on macrophage phagocytosis, 69–70
\(\mu\text{-Opioid}\) receptor-deficient (MORKO) mice
corticosterone levels in, 120–121, 122–123, 124
effect of chronic morphine injection on, 117–124
production of, 117–118
Opioid receptors
cross-desensitization with chemokine receptors, 69–74, 75–79
interaction with chemokines, 71–73
Opioid resistance, of inbred rat strains, 62
Opportunistic infections, intravenous drug abusers' susceptibility to, 83
Organophosphates, neurotoxicity of, 7
Outer submucosal plexus, 198
Ovary, cannabinoid receptor; distribution in, 216
Parasitic infections, neurotropic, 2
Paraventricular nucleus, in morphine tolerance, 178, 181, 182, 183
Peripheral blood monocyte cells
cannabinoid receptor mRNA expression by, 229–233
cocaine-modulated chemokine receptor expression by, 238–239
cocaine-modulated macrophage inflammatory protein-β expression by, 238–239
Peristalsis
morphine-induced inhibition of, 174
opioid-induced inhibition of, 197
Peterson, Phillip K., 263
Peyer’s patches
bacterial invasion of, 174
enteric neural control of, 202–203
by Salmonella, 174
immunologic function of, 201
neurotransmitter/neuromodulator substances of, 202
Phagocytosis
effect of anandamide on, 207–208
effect of opioid-selective agonists on, 69–70
self-enhanced, effect of morphine on, 111–116
Phencyclidine (PCP), neurotoxicity of, 7
Phytohemagglutinin (PHA), effect of \(\kappa\text{-opioid}\) receptor expression, on T cells, 106, 107, 109
Placenta, cannabinoid receptor; distribution in, 216
Polioviruses, intestinal invasion by, 202
Poly-(ADP-ribose) polymerase (PARP); in opiate-induced T-cell apoptosis, 127, 131–132, 133
Porcine ileus
mucosal defense mechanisms of, effect of opioids and cannabinoids on, 199–201
Porcine ileus (cont.)
opioid and cannabinoid receptors of, 198–199
Positron emission tomography, use in cognitive function assessment, 15
Prion infections, neurotropic, 2
Proenkephalin A, expression by CD4+ , CD8-double negative T cells, 163
Proopi melanocortin (POMC), 62, 63
as peptide hormone source, 137
Prostaglandin E2 as intestinal inflammatory mediator, 200, 201
Prostate gland, cannabinoid receptor1 distribution in, 216
Protein 10
interferon-inducible, cocaine-related secretion of, 39
Protein 10, µ-opioid agonist-induced expression of, 70
Protein-1α, 3
Protein kinase, cAMP-dependent, in long-term potential, 18–19, 20
Proton magnetic resonance spectroscopy, 15
Psilocybin, neurotoxicity of, 7
Reoviruses, 216
Psyllium, antihypertensive activity of, 216–217
RANTES
HIV entry co-receptor binding by, 235
microglia chemotaxis toward, morphine-induced inhibition of, 3
µ-opioid agonist-induced expression of, 70
effect on opioid-induced chemotaxis, 76, 77, 78
opioid receptor desensitizing action of, 72
Retroviruses, intestinal invasion by, 202
Rheumatoid arthritis, β-endorphins in, 140–141
Rodent memory analysis systems, 9–14
brain imaging and cognitive testing, 14–15
hippocampal models, 15–21
passive avoidance tests (PAT), 13–14
prototypical paradigms for, 9, 10
radial arm-maze (RAM), 9, 10
Rogers, Thomas, 257
Royal, Walter, 260
Saint John’s wort, HIV-suppressing action of, 3, 4
Salmonella
differentiation of, 202–203
intestinal invasion by, 202
Salmonellosis
HIV infection-associated, 170, 173
oral, opioids-induced potentiation of, 169–176
effect of κ-opioid agonists on, 171, 174
mechanism of, 174
plaque-forming cell assay of, 170–171
substance P receptor mRNA expression in, 249
substance P/substance P receptor interactions in, 249–250
SDF-1α, in HIV-related neurodegeneration, 31
SEB, see Staphylococcal enterotoxin B
Sepsis, morphine-associated, 174
Serotonin, as intestinal inflammatory mediator, 200, 201
Sharp, Burt, 256
Sheep red blood cells, phagocytosis by, effect of morphine on, 112–115
Shigella, intestinal invasion by, 202
Shock, endotoxin, opioid-dependent pathways in, 195
Simian immunodeficiency virus-infected monkeys, central nervous system disease induction in, 260
Singhal, Pravin, 257–258
Single-photon emission tomography (SPECT), for cognitive function assessment, 15
Skin graft survival time, effect of β-endorphins on, 140, 141
Small intestine, mucosal secretory defenses of, effect of opioids and cannabinoids on, 199–201
Spleen
cannabinoid receptor, distribution in, 216
effect of heroin on, 153–162
apoptotic cell increase, 156–159, 160–161
B cell proliferation decrease, 152–153, 159–160
interferon-γ decrease, 152–153, 159–160
leukocyte decrease, 142–150, 154–156, 160, 161
natural killer cell cytotoxicity decrease, 152–153, 155, 159, 161
T cell proliferation decrease, 152–153, 155, 159–160
total leukocyte number, 155, 161
morphine-induced reduction in, 123
Splenocytes
cannabinoid receptor expression on, 215–221
Friend leukemia virus-infected, Fas/FasL expression in, 145–149
lipopolysaccharide-stimulated cannabinoid receptor2 mRNA expression in, 223–228
mitogen-activated, κ-opioid receptor expression by, 100–110
δ-opioid receptor mRNA expression in, 256
opioid receptors of, 103
SR144716A, reversal of cannabinoid-induced nitric oxide inhibition by, 210–211, 213, 256
Staphylococcal enterotoxin B
effect on δ-opioid receptor mRNA expression, 256
effect on thymic T cell development, 163–167
Stomach, cannabinoid receptor distribution in, 216
Stress, effect on T-cell recirculation, 96–98
Stromal cell-derived factor-α, opioid receptor desensitizing action of, 72, 73
Substance P receptors
effect on macrophage activities and functions
immune response amplification, 252–253
intracellular signaling, 247–248
monokine secretion, 248–249
preprotachykinin expression, 249
in salmonellosis, 249–250
expression on macrophages, 250–251
Superantigen, effect on thymic T cell development, 163–167

Tat protein
in HIV-related neurodegeneration, 30, 31, 32
monocyte chemotactic protein-induced upregulation by, 259
neurotoxicity of, in cocaine abuse, 243, 244
T-cell receptors, opioid-receptor mRNA expression on, 256
T cells
heroin-related decrease in, 152–153, 155, 159–160
thymic development of, effect of staphylococcal enterotoxin B on, 163–167
Testis, cannabinoid receptor distribution in, 216

Th1
cytokine production by, 138
effect of naloxone on, 138, 139–140
FasL expression by, 143
interferon-γ production by, in substance P receptor expression, 252

Th2
cytokine production by, 138
effect of naloxone on, 138, 139–140
interleukin-4 production by, in substance P receptor expression, 252
Th1/Th2 balance
effect of cocaine on, 39
effect of endorphins on, 137–141
Thalidomide, HIV-suppressing action of, 3, 4
Thymocytes
κ-opioid receptor expression on, 108, 256–257
Thymocytes (cont.)
primary murine, opioid responsiveness of, 75–79
Thymus
cannabinoid receptor 1 distribution in, 216
morphine-induced atrophy in, 121–123, 124
Toluene, neurotoxicity of, 7
Tonsils, cannabinoid receptor 1 distribution in, 216
Toxins, as neurodegeneration cause, 7

Transmembrane G-protein coupled receptors, lymphocyte modulation by, 255–258
Tryptase, as intestinal inflammatory mediator, 200, 201

Tumor growth factor-β
in HIV-related neurodegeneration, 32
substance P-induced inhibition of, 248
Tat protein-induced activation of, 31
Tumor necrosis factor-α
cocaine-induced secretion of, 39
effect on HIV-infected astrocytes, 259
effect on HIV neuroinvasion, 36
μ-opioid agonist-induced inhibition of, 70
peritoneal macrophage production of, U50,488-related inhibition of, 108
tumor growth factor-β-induced activation of, 31
U50,488
immunosuppressive effects of, 103, 173
in oral salmonellosis, 173, 174
effect on thymic T-cell development, 163
Uterus, cannabinoid receptor distribution in, 216
Uveitis, experimental autoimmune, genomic loci of, 64–65
VCAM (adhesion molecule), morphine-induced expression of, 189–190
Viral infections, neurotropic, 2
Vpr protein, in human immunodeficiency virus-related neurodegeneration, 30
Withdrawal, as anxiety cause, 63

Yersinia, intestinal invasion by, 202